BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Olumiant (baricitinib) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Olumiant (baricitinib)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07843693-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Olumiant (baricitinib): Phase 1 readout est. (NCT07843693)
DESCRIPTION:Olumiant (baricitinib)\, phase 1.\nStudy: A Study to Evaluate t
 he Safety and Pharmacokinetics of Multiple Doses Upadacitinib\, Tofacitini
 b\, and Baricitinib in Healthy Adult Volunteers\nEstimated primary complet
 ion: December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 aricitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07843693
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06548802-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Olumiant (baricitinib): Phase 1/2 readout est. (NCT06548802)
DESCRIPTION:Olumiant (baricitinib)\, phase 1/2.\nStudy: Efficacy and Safety
  of Baricitinib in the Post-intracerebral Hemorrhage Pulmonary Injury\nEst
 imated primary completion: 31 December 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/baricitinib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06548802
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06439615-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Olumiant (baricitinib): Phase 2 readout est. (NCT06439615)
DESCRIPTION:Olumiant (baricitinib)\, phase 2.\nStudy: Baricitinib for the L
 ung Injury Following Spontaneous SAH\nEstimated primary completion: 31 Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/baricitin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6439615
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04870203-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Olumiant (baricitinib): Phase 3 readout est. (NCT04870203)
DESCRIPTION:Olumiant (baricitinib)\, phase 3\, Rheumatoid Arthritis.\nStudy
 : Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis\nEstimat
 ed primary completion: March 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/baricitinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT04870203
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05792462-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Olumiant (baricitinib): Phase 1 readout est. (NCT05792462)
DESCRIPTION:Olumiant (baricitinib)\, phase 1.\nStudy: Efficacy and Safety o
 f Baricitinib in Neuromyelitis Optica Spectrum Disorders\nEstimated primar
 y completion: 1 March 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/baricitinib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05792462
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06849908-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Olumiant (baricitinib): Phase 2 readout est. (NCT06849908)
DESCRIPTION:Olumiant (baricitinib)\, phase 2.\nStudy: Baricitinib in the Tr
 eatment of Intestinal Behçet's Syndrome\nEstimated primary completion: 30
  June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/baricitin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6849908
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05003310-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Olumiant (baricitinib): Phase na readout est. (NCT05003310)
DESCRIPTION:Olumiant (baricitinib)\, phase na\, Rheumatoid Arthritis.\nStud
 y: ConsideRAte Study - Splenic Stimulation for RA\nEstimated primary compl
 etion: July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bar
 icitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05003310
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07449910-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270817
DTEND;VALUE=DATE:20270818
SUMMARY:Olumiant (baricitinib): Phase 2/3 readout est. (NCT07449910)
DESCRIPTION:Olumiant (baricitinib)\, phase 2/3.\nStudy: Safety and Efficacy
  of Baricitinib After Endovascular Treatment in Acute Anterior Circulation
  Large Vessel Occlusion: A Multicenter\, Randomized Controlled Clinical Tr
 ial\nEstimated primary completion: 17 August 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/baricitinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07449910
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07608796-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Olumiant (baricitinib): Phase 2 readout est. (NCT07608796)
DESCRIPTION:Olumiant (baricitinib)\, phase 2.\nStudy: JAK Signaling in Depr
 ession and Cognition in Male Football Players\nEstimated primary completio
 n: October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bari
 citinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07608796
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05849038-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Olumiant (baricitinib): Phase 2 readout est. (NCT05849038)
DESCRIPTION:Olumiant (baricitinib)\, phase 2.\nStudy: Inflammation and Depr
 ession in People With HIV\nEstimated primary completion: November 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/baricitinib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05849038
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07535645-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Olumiant (baricitinib): Phase 1/2 readout est. (NCT07535645)
DESCRIPTION:Olumiant (baricitinib)\, phase 1/2.\nStudy: Baricitinib for Pos
 t-HSCT Persistent Thrombocytopenia\nEstimated primary completion: 31 Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/baricitinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075
 35645
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07669675-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Olumiant (baricitinib): Phase 2 readout est. (NCT07669675)
DESCRIPTION:Olumiant (baricitinib)\, phase 2.\nStudy: TPO-RA Plus Baricitin
 ib vs. TPO-RA for ITP\nEstimated primary completion: 31 December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/baricitinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07669675
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05452564-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Olumiant (baricitinib): Phase 2 readout est. (NCT05452564)
DESCRIPTION:Olumiant (baricitinib)\, phase 2.\nStudy: Baricitinib for Reduc
 tion of HIV - CNS\nEstimated primary completion: January 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/baricitinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05452564
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07209267-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Olumiant (baricitinib): Phase 2 readout est. (NCT07209267)
DESCRIPTION:Olumiant (baricitinib)\, phase 2.\nStudy: Baricitinib Curative 
 Repression of HIV-1\nEstimated primary completion: January 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/baricitinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07209267
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04972760-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Olumiant (baricitinib): Phase 3 readout est. (NCT04972760)
DESCRIPTION:Olumiant (baricitinib)\, phase 3.\nStudy: Baricitinib in Patien
 ts With Relapsing or naïve Dermatomyositis\nEstimated primary completion:
  28 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ba
 ricitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04972760
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03414502-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Olumiant (baricitinib): Phase 3 readout est. (NCT03414502)
DESCRIPTION:Olumiant (baricitinib)\, phase 3\, Rheumatoid Arthritis.\nStudy
 : Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response\nE
 stimated primary completion: March 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/baricitinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT03414502
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05723198-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Olumiant (baricitinib): Phase 3 readout est. (NCT05723198)
DESCRIPTION:Olumiant (baricitinib)\, phase 3\, Alopecia Areata.\nStudy: A S
 tudy of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Y
 ears of Age With Alopecia Areata\nEstimated primary completion: March 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/baricitinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05723198
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02735707-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Olumiant (baricitinib): Phase 3 readout est. (NCT02735707)
DESCRIPTION:Olumiant (baricitinib)\, phase 3\, COVID-19.\nStudy: Randomized
 \, Embedded\, Multifactorial Adaptive Platform Trial for Community- Acquir
 ed Pneumonia\nEstimated primary completion: June 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/baricitinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT02735707
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222332-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Olumiant (baricitinib): Phase 3 readout est. (NCT07222332)
DESCRIPTION:Olumiant (baricitinib)\, phase 3.\nStudy: A Study of Baricitini
 b (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly 
 Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)\nEstimated primary comp
 letion: July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ba
 ricitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07222332
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06868381-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Olumiant (baricitinib): Phase 2 readout est. (NCT06868381)
DESCRIPTION:Olumiant (baricitinib)\, phase 2.\nStudy: A Trial of Baricitini
 b in Patients With Cardiac Sarcoidosis\nEstimated primary completion: 1 Ju
 ly 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/baricitinib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0686
 8381
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06381661-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20280809
DTEND;VALUE=DATE:20280810
SUMMARY:Olumiant (baricitinib): Phase 2 readout est. (NCT06381661)
DESCRIPTION:Olumiant (baricitinib)\, phase 2.\nStudy: Adaptive Platform Tri
 al for Personnalisation of Sepsis Treatment in Children and Adults: a Mult
 i-national\, Treatable Traits-guided\, Adaptive\, Exploratory\, Bayesian B
 asket Trial\nEstimated primary completion: 9 August 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/baricitinib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06381661
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06490757-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20280902
DTEND;VALUE=DATE:20280903
SUMMARY:Olumiant (baricitinib): Phase 2 readout est. (NCT06490757)
DESCRIPTION:Olumiant (baricitinib)\, phase 2.\nStudy: A Phase 2 Open-label 
 Single-arm Trial of JAK1 Inhibitor for the Treatment of Large Inflammatory
  Hepatocellular Adenomas\nEstimated primary completion: 2 September 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/baricitinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06490757
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04381936-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Olumiant (baricitinib): Phase 3 readout est. (NCT04381936)
DESCRIPTION:Olumiant (baricitinib)\, phase 3\, COVID-19.\nStudy: Randomised
  Evaluation of COVID-19 Therapy\nEstimated primary completion: 30 Septembe
 r 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/baricitinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04381
 936
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07279688-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Olumiant (baricitinib): Phase 3 readout est. (NCT07279688)
DESCRIPTION:Olumiant (baricitinib)\, phase 3.\nStudy: Justification And Eva
 luation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone i
 n pOlymyalgia RhEumatica\nEstimated primary completion: November 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/baricitinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07279688
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06687551-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20290401
DTEND;VALUE=DATE:20290402
SUMMARY:Olumiant (baricitinib): Phase 4 readout est. (NCT06687551)
DESCRIPTION:Olumiant (baricitinib)\, phase 4\, Rheumatoid Arthritis.\nStudy
 : JAK Inhibitor Dose TAPering Strategy Study\nEstimated primary completion
 : 1 April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/baric
 itinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06687551
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07081763-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Olumiant (baricitinib): Phase 2 readout est. (NCT07081763)
DESCRIPTION:Olumiant (baricitinib)\, phase 2.\nStudy: Immunotherapy With Ba
 ricitinib and Sirolimus\, Alone and in Combination\, for the Control of HI
 V-1 Replication After Antiretroviral Treatment Interruption\nEstimated pri
 mary completion: May 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/baricitinib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07081763
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07779642-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Olumiant (baricitinib): Phase 2 readout est. (NCT07779642)
DESCRIPTION:Olumiant (baricitinib)\, phase 2.\nStudy: Precision Medicine Ad
 aptive Network Platform Trial in Hypoxemic Acute Respiratory Failure\nEsti
 mated primary completion: September 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/baricitinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07779642
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07268534-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Olumiant (baricitinib): Phase 2 readout est. (NCT07268534)
DESCRIPTION:Olumiant (baricitinib)\, phase 2.\nStudy: Biologics in Follicul
 itis Decalvans : an Adaptative Trial Research\nEstimated primary completio
 n: 1 November 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 aricitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07268534
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05651880-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Olumiant (baricitinib): Phase 3 readout est. (NCT05651880)
DESCRIPTION:Olumiant (baricitinib)\, phase 3.\nStudy: Efficacy and Toleranc
 e of Baricitinib\, a JAK Inhibitor\, in the Treatment of Refractory Non-in
 fectious Non-anterior Uveitis\nEstimated primary completion: December 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/baricitinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05651880
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07003997-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Olumiant (baricitinib): Phase 2 readout est. (NCT07003997)
DESCRIPTION:Olumiant (baricitinib)\, phase 2.\nStudy: JAK Signaling in Depr
 ession\nEstimated primary completion: February 2030. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/baricitinib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07003997
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07262983-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20300501
DTEND;VALUE=DATE:20300502
SUMMARY:Olumiant (baricitinib): Phase 1 readout est. (NCT07262983)
DESCRIPTION:Olumiant (baricitinib)\, phase 1\, Atopic Dermatitis.\nStudy: E
 valuating the Safety and Tolerability of Baricitinib in Patients With Job 
 Syndrome With Lupus-Like Disease and/or Atopic Dermatitis\nEstimated prima
 ry completion: 1 May 2030. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/baricitinib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07262983
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07543458-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Olumiant (baricitinib): Phase 3 readout est. (NCT07543458)
DESCRIPTION:Olumiant (baricitinib)\, phase 3.\nStudy: Therapeutics for Mode
 rate and Severe Dengue\nEstimated primary completion: 31 July 2030. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/baricitinib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07543458
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06923072-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20301214
DTEND;VALUE=DATE:20301215
SUMMARY:Olumiant (baricitinib): Phase 2 readout est. (NCT06923072)
DESCRIPTION:Olumiant (baricitinib)\, phase 2.\nStudy: Baricitinib in the Tr
 eatment of Kohlmeier-Degos Disease in Patients With Neurological Involveme
 nt\nEstimated primary completion: 14 December 2030. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/baricitinib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06923072
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222137-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20310731
DTEND;VALUE=DATE:20310801
SUMMARY:Olumiant (baricitinib): Phase 3 readout est. (NCT07222137)
DESCRIPTION:Olumiant (baricitinib)\, phase 3.\nStudy: A Study of Baricitini
 b (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children
  and Adults\nEstimated primary completion: July 2031. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/baricitinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07222137
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03773965-98@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20310731
DTEND;VALUE=DATE:20310801
SUMMARY:Olumiant (baricitinib): Phase 3 readout est. (NCT03773965)
DESCRIPTION:Olumiant (baricitinib)\, phase 3.\nStudy: A Study of Baricitini
 b in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idio
 pathic Arthritis\nEstimated primary completion: July 2031. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/baricitinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT03773965
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
